(Q46846032)

English

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16342165

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy (English)

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16342165

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

2

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

25 December 2017

8

object named as

Stefan Faderl

1 reference

Europe PubMed Central

25 December 2017

5

object named as

Susan O'Brien

1 reference

Europe PubMed Central

25 December 2017

Gautam Borthakur

1

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

25 December 2017

7

object named as

Francis Giles

1 reference

Europe PubMed Central

25 December 2017

Guillermo Garcia-Manero

6

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

25 December 2017

Jorge Eduardo Cortes

10

object named as

Jorge Cortes

1 reference

Europe PubMed Central

25 December 2017

George Q. Daley

3

object named as

George Daley

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16342165

4

object named as

Moshe Talpaz

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16342165

author name string

Mary Sugrue

9

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16342165

language of work or name

0 references

publication date

1 January 2006

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16342165

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16342165

106

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16342165

346-352

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16342165

2

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16342165

Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

21 January 2018

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Protein prenylation, et cetera: signal transduction in two dimensions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

RAS and leukemia: from basic mechanisms to gene-directed therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Punish the parent not the progeny.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21590

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21590

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16342165

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16342165

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46846032&oldid=2134527706"